SpringWorks Therapeutics Announces Pricing Of Initial Public Offering

NEXT STORY
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
PREV STORY
Castle Creek Pharmaceutical Holdings to Acquire Fibrocell
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

IMARC Celebrates 20 Years of Supporting Clinical Research

STRONGSVILLE, Ohio, Nov. 12, 2018 (GLOBE NEWSWIRE) -- IMARC, a leading clinical research organization, ...

author_avatar
NASDAQ Market News

Tempus Launches Tempus xE, Whole Exome Sequencing to Empower Data-Driven Cancer Care and Research

CHICAGO, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping ...

author_avatar
NASDAQ Market News

TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study of Patients with Advanced Pancreatic Cancer

68% of evaluable patients with actively progressing end-stage pancreatic cancer receiving monotherapy SM-88 remain ...

author_avatar
NASDAQ Market News